Active substance
Albendazole
- SFDA 2
- US FDA 10
- US price lines 1
- WHO EML 3
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ALBENDA 100MG\5ML SUSP | 20 mg/ml | Suspension · Oral use | 1 Bottle | SAR 12.20 | NCE · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| ALBENDA 200 MG TAB | 200 mg | Film-coated tablet · Oral use | 2 Blister | SAR 6.15 | NCE · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ASCARIASIS; GIARDIA LAMBLIA INFECTION; HOOKWORM; HOOKWORM-CUTANEOUS LARVA MIGRANS; PINWORM (ENTEROBIASIS, OXYURIASIS, THREADWORM); STRONGYLOIDIASIS; TAENIASIS; TRAVEL RELATED INFECTIONS-TREATMENT; TRICHINELLOSIS (ALSO KNOWN AS TRICHINOSIS); TRICHURIASIS (ALSO KNOWN AS WHIPWORM INFECTION)
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ALBENDAZOLE | 200MG | tablet · oral | ZYDUS PHARMS | Prescription | 14 Dec 2018 |
| ALBENDAZOLE | 200MG | tablet · oral | EDENBRIDGE PHARMS | Prescription | 14 May 2019 |
| ALBENDAZOLE | 200MG | tablet · oral | ACTAVIS ELIZABETH | Prescription | 20 May 2019 |
| ALBENDAZOLE | 200MG | tablet · oral | MSN | Prescription | 22 Jan 2021 |
| ALBENDAZOLE | 200MG | tablet · oral | DR REDDYS | Prescription | 26 Jan 2021 |
| ALBENDAZOLE | 200MG | tablet · oral | ALEMBIC | Prescription | 4 Sep 2024 |
| ALBENZA | 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | IMPAX LABS INC | Discontinued | 11 Jun 1996 |
| ALBENDAZOLE | 200MG | tablet · oral | CIPLA LTD | Discontinued | 21 Sep 2018 |
| ALBENDAZOLE | 200MG | tablet · oral | STRIDES PHARMA | Discontinued | 7 Dec 2018 |
| ALBENDAZOLE | 200MG | tablet · oral | CHARTWELL RX | Discontinued | 10 Jun 2020 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ALBENDAZOLE 200 MG TABLET | $4.14581 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.1.1. Intestinal anthelminthics · core
Echinococcosis; Cysticercosis; Hookworm diseases; Trichuriasis; Ascariasis; Enterobiasis
Oral > Solid > tablet: 400 mg (chewable, scored) - 6.1.4. Cysticidal medicines · complementary
Other specified echinococcosis; Cysticercosis of central nervous system
Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable) (EMLc) - 6.1.2. Antifilarials · core
Lymphatic filariasis
Oral > Solid > tablet: 400 mg (chewable, scored)
Safety signals and safety-related labeling changes
- US FDA 11 Jul 2019 ALBENZA — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.